New Search

If you are not happy with the results below please do another search

Search
Generic filters

50 search results for:

1

Abbott Enters into Consent Decree with U.S. Food and Drug Administration for its Sturgis, Mich., Plant; Agreement Creates Pathway to Reopen Facility

/in , , , , , , , , ,

Abbott agreed to enter into a consent decree with the U.S. Food and Drug Administration related to the company’s Sturgis, Mich., infant formula plant. The decree is an agreement between the FDA and Abbott on the steps necessary to resume production and maintain the facility. This does not affect any other Abbott plant or operation. The decree is subject to court approval.

2

Lacking vaccines, North Korea battles COVID with antibiotics, home remedies

/in , , , , , , ,

Standing tall in bright red hazmat suits, five North Korean health workers stride towards an ambulance to do battle with a COVID-19 outbreak that – in the presumed absence of vaccines – the country is using antibiotics and home remedies to treat. The isolated state is one of only two countries yet to begin a vaccination campaign and, until last week, had insisted it was COVID-free. Now North Korea is mobilizing forces including the army and a public information campaign to combat what authorities have acknowledged is an “explosive” outbreak.

4

Positive Clinical Results Advance Treatments For Multiple Myeloma, Asthma, Alzheimer’s

/in , , , , , , , , , , , , , ,

In recent months, the biotech and biopharma industries have been struggling with layoffs and dropping stocks. However, some companies are still experiencing success. Sanofi, AstraZeneca, Avillion and Diadem recently announced positive clinical results, providing positive news for patients with multiple myeloma, asthma and Alzheimer’s disease.

5

Shanghai targets June COVID lockdown exit as China economy slumps

/in , , , , , , , , , , , , , , , , , , , , , , , , , , ,

Shanghai set out plans on May 16 for the end of a painful COVID-19 lockdown that has lasted more than six weeks, heavily bruising China’s economy, and for the return of more normal life from June 1.

7

BMS, Synairgen regroup after trials miss primary endpoints

/in , , , , , , , , , , ,

Bristol Myers Squibb shared the news that the company’s Phase III clinical trial investigating the safety and efficacy of Opdivo and Yervoy combination therapy (NCT03036098) in patients with metastatic urothelial carcinoma failed to meet the predetermined primary endpoint. A posthoc analysis was shared by Synairgen suggesting that, despite SNG001 failing to meet the primary endpoint of patient recovery and subsequent hospital discharge in a Phase III study for patients hospitalized with COVID-19 who required supplemental oxygen treatment, they may benefit from receiving the treatment.

8

N. Korea’s Kim orders military to stabilize supply of COVID drugs

/in , , , , , , , , , ,

Leader Kim Jong Un ordered North Korea’s military to stabilize distribution of COVID-19 medicine in the capital, Pyongyang, in the battle against the country’s first confirmed outbreak of the disease, state media said.

10

Eli Lilly deals another blow to diabetes with latest FDA approval

/in , , , , , , , , , , , ,

Eli Lilly scored another win against diabetes as the company’s once-weekly dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist tirzepatide won approval under Priority Review from the U.S. Food and Drug Administration.